BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/20/2017 10:12:50 AM | Browse: 977 | Download: 1445
 |
Received |
|
2017-02-09 09:35 |
|
Peer-Review Started |
|
2017-02-09 17:06 |
|
To Make the First Decision |
|
2017-03-16 11:51 |
|
Return for Revision |
|
2017-03-21 11:35 |
|
Revised |
|
2017-04-05 16:46 |
|
Second Decision |
|
2017-04-27 18:13 |
|
Accepted by Journal Editor-in-Chief |
|
2017-04-27 19:50 |
|
Accepted by Company Editor-in-Chief |
|
2017-05-04 18:32 |
|
Articles in Press |
|
2017-05-04 18:32 |
|
Publication Fee Transferred |
|
2017-06-16 20:55 |
 |
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-07-19 04:32 |
|
Publish the Manuscript Online |
|
2017-07-20 10:12 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Uri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Gerald Wayne Dryden, Jianmin Pan, Shesh Nath Rai and Susan Galandiuk |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Susan Galandiuk, MD, FACG, AGAF, Price Institute of Surgical Research, The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville School of Medicine, 550 South Jackson Street, Louisville, KY 40202, United States. s0gala01@louisville.edu |
| Key Words |
Anti-tumor necrosis factor; Fas ligand; antibody; response; Crohn’s disease; single nucleotide polymorphisms; genotype; tumor necrosis factor gene |
| Core Tip |
Predicting the subset of patients who do not respond to anti-tumor necrosis factor (TNF) treatment is important clinically and economically. Patients with Crohn’s disease who received anti-TNF therapy were grouped as ever-responders or non-responders. Genomic DNA was extracted from peripheral blood, and 7 single nucleotide polymorphisms (SNPs) were assessed. 121 patients were included. Twenty-one were non-responders, and 100 were ever-responders. Fas ligand SNP (rs763110) genotype frequencies, TNF gene -308 SNP (rs1800629) genotype frequencies, and their combination, were significantly different between groups on multivariable analysis and may help select patients likely to benefit from anti-TNF therapy. |
| Publish Date |
2017-07-20 10:12 |
| Citation |
Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol 2017; 23(27): 4958-4967 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i27/4958.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i27.4958 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
